We believe that our lead candidate, APH-012, has the potential to revolutionize the treatment of metabolic diseases like obesity and type 2 diabetes. APH-012 uniquely induces the release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.


Phase 2 Trial in Obesity

APH-012 is being evaluated in a Phase 2 proof-of-concept study in individuals with obesity The trial will evaluate APH-012’s ability to change individual’s percent weight compared to placebo, in addition to other key parameters which are hallmarks of multiple metabolic diseases closely associated with obesity.


Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of metabolic diseases, today announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic diseases, today announced that it has enrolled the first patient as part of a Phase 2 study evaluating the safety and efficacy of its lead drug candidate, APH-012, to induce weight loss in individuals with obesity.